Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamidronate one-day versus three-day regimen in fibrous dysplasia of bone
RBR-7t8qnj8Phase 3Recruiting
- Sponsor
- Universidade Estadual Paulista
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pamidronate in fibrous dysplasia (2 arms), sponsored by Universidade Estadual Paulista. Primary endpoints: Safety and Cost. Started May 2022; status: recruiting.
02
Drugs
pamidronate
03
Conditions
fibrous dysplasia
Beyond the preview
Go deeper on RBR-7t8qnj8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7t8qnj8.